Loading provider…
Loading provider…
Surgery Physician in Houston, TX
NPI: 1306932074Primary Employer
Physicians Referral Service
mdanderson.org
HQ Phone
Get M.D. Funda's Phone Numberphone_androidMobile
Get M.D. Funda's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardTX State Medical License
FL State Medical License
2021
AZ State Medical License
2023 - 2026
GA State Medical License
2023 - 2026
MS State Medical License
2023 - 2026
OK State Medical License
2020 - 2026
TN State Medical License
2023 - 2026
TX State Medical License
1999 - 2026
AL State Medical License
2023 - 2025
LA State Medical License
2023 - 2025
WA State Medical License
2023 - 2025
MI State Medical License
1996 - 2000

American Board of Preventive Medicine
Clinical Informatics

American Board of Surgery
Surgery
Yale School of Medicine
medicine.yale.edu
Medical School
Until 1991
University of Michigan
Residency • Surgery
1991 - 1998
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 63 | 151 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 18 | 18 |
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances.
Authors: Guidi, Lorenzo, Etessami, Julian, Valenza, Carmine, Valdivia, Augusto, Meric-Bernstam, Funda, Felip, Enriqueta, Curigliano, Giuseppe
Journal: Am Soc Clin Oncol Educ Book
Publication Date: 2025-04-08
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers.
Authors: Mariya Rozenblit, Julia Foldi, Kevin Kalinsky, Lajos Pusztai
Journal: NPJ Breast Cancer
Publication Date: 2022-11-07
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: PDR001
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Abemaciclib, DRUG: Fulvestrant, DRUG: Paclitaxel, DRUG: Imlunestrant, DRUG: LOXO-783, DRUG: Anastrozole, Exemestane, or Letrozole
Lead Sponsor: AbbVie
Intervention / Treatment: DRUG: IMGN151